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Background: Extravasation injury remains an important cause of iatrogenic injury in neonatal intensive care. This
study aims to describe the current approach to extravasation injury (EI) prevention and management in Neonatal
Intensive Care Units (NICUs) in Australia and New Zealand.
Methods: A literature review regarding extravasation injury in the newborn was carried out to inform questionnaire
design. An internet-based survey was then conducted with the clinical directors of the 27 tertiary NICUs in Australia
and New Zealand.
Results: The survey received a 96% response rate. Approximately two thirds of Australian and New Zealand NICUs
have written protocols for prevention and management of extravasation injury. Considerable practice variation was
seen for both prevention and treatment of EI. 92% of units had experienced cases of significant EI.
Conclusions: Australian and New Zealand tertiary neonatal units clearly recognise EI as an important cause of
iatrogenic morbidity and mortality. Significant variation still exists among units with regards to guidelines for both
prevention and management of EI. We recommend that neonatal staff should remain vigilant, ensuring that
guidelines for the prevention and treatment of EI are available, and rigorously followed.
Keywords: Neonate, Extravasation, Injury, Hyaluronidase, IntravenousBackground
The use of intravenous (IV) access for provision of nu-
trition and medication is essential in modern neonatal
intensive care. Neonatal veins are small and fragile, and
intravenous lines are often required for long periods of
time. This, in combination with a neonate’s inability to
communicate clearly, increases their susceptibility to
extravasation injury (EI). EI occurs when fluid from an
IV line leaks into the surrounding tissues or other
extra-vascular space. Tissue damage occurs as a result
of differences in physiochemical characteristics, includ-
ing pH and osmolarity, between the extravasate sub-
stance and the host tissue [1]. Depending on IV line
location (central or peripheral), the infiltrate can cause
damage potentially resulting in: skin loss, tendon and* Correspondence: Ben.wheeler@otago.ac.nz
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reproduction in any medium, provided the ornerve damage, limb amputation, [2] and central injuries
(e.g. hepatic and cardiac). Commonly used neonatal in-
fusions prone to EI include: total parenteral nutrition
(TPN), calcium, potassium, bicarbonate, and dextrose
in high concentrations. Some particular intravenous
medications are also well known for their potential to
cause EI such as: acyclovir, vancomycin, and inotropes
e.g. dopamine [3].
A number of studies have looked at rates of EI in neo-
natal intensive care units (NICUs). A 1985 [4] study of
100 NICU survivors 16–29 months following discharge
identified 61% as having scars consistent with an EI. A
grading system ranging from grade 1 (barely perceptible)
to grade 4 (functionally significant) was used to indicate
the severity of the scarring. While the vast majority of
these cases had only minor scarring, four cases had scar-
ring deemed cosmetically or functionally significant. A
more recent study [5] from the United Kingdom found
that 38/1000 neonates undergoing neonatal intensiveral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of main survey findings
Recognition & prevention of EI:
Units with written policy/standard practice 24/26 (92%)
Of these, policy includes:
Regular nursing observations: 21/24 (88%)
Keeping skin over tip of line visible 18/24 (75%)
Line flush before drug administration 14/24 (58%)
Treatment of EI:
Units with written policy/standard practice 24/26 (92%)
Of these, treatment policy includes:
Immediate line removal 21/24 (88%)
Limb elevation 15/24 (63%)
Saline washout via small incisions 16/24 (67%)
Hyaluronidase 9/24 (38%)
Warm or cold compress 1/24 (4%)
Complications of EI:




Cardiac Tamponade (with associated deaths in 2 units) 13/26 (50%)





Limb endangering 6/26 (23%)
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crosis. The majority of these injuries were at gestations
26 weeks or less (ranging from 23–35 weeks).
Numerous treatment protocols have been published
on the management of EI. The only step common to all
is that the intravenous infusion should be stopped im-
mediately. Recent protocols appear to favour the use of
hyaluronidase injection plus saline flush in the treatment
of EI [2,6-8]. However, there are many other treatment
regimes described including the use of various creams,
ointments, and occlusive dressings. Specific treatments
are also available depending on the infusate e.g. topical
nitroglycerin for vasoactive medications [9].
Despite the growing literature in this area, there ap-
pears to be little consensus between units and countries
on how EI should be prevented and/or treated with
much of the available evidence coming from case reports
and clinical reviews. No studies have been done looking
specifically at current practice across NICUs. With this
in mind, we utilised the Australian and New Zealand
Neonatal Network (ANZNN), to conduct an internet-
based survey exploring current practice in tertiary neo-
natal units concerning EI prevention and management.
Methods
27 NICUs providing tertiary care (defined by the
ANZNN as providing regular advanced airway support/
intensive care) were identified using the 2012 ANZNN
directory. This included 21 units in Australia and six in
New Zealand. All units were contacted over a 4 week
period during June/July, 2012. In the first instance, the
Clincal Director/Head of each unit was contacted by
email and invited to participate in the survey. This was
to ensure the most consistent and authoritative response
to questions regarding unit extravasation treatment
practices. Informed consent consisted of an explanation
of the survey and its purpose given in an email to all po-
tential participants, with consent done via an email link
which connected directly to a Survey Monkey™ internet
based questionnaire (see Additional file 1).
In eight instances, where there was difficulty in
contacting the Director, the Deputy Director or a staff
neonatologist was contacted to provide this information.
All data was confidentially and automatically stored on-
line at completion of the survey for later analysis.
Survey content was informed by a literature review. This
involved an Ovid MEDLINE search for relevant articles
published between 1946 and 2012 using the following
words or terms: Neonates, extravasation, peripheral cannu-
lae, neonatal intensive care, scars, dopamine, total paren-
teral nutrition, infiltration, ischaemia, alpha-adrenergic,
receptor, complications, therapy, intravenous.
Units were excluded from our survey if they were not
classified as providing tertiary level neonatal care withinthe ANZNN. The two listed neonatal emergency transport
services in Australia were also excluded. Ethics approval
was provided by the University of Otago ethics committee.
Results
Responses were obtained from 26/27 units, giving a 96%
response rate. Table 1 gives a summary of our findings.
Prevention
A written policy for the prevention and recognition of EI
was used by 69% (18/26) of units. A further 23% (6/26)
had no written policy but utilised a standard practice.
8% (2/26) of units had no written policy or standard
practice. Broken down by country, 83% (5/6) of the New
Zealand units had a written policy, compared to 65%
(13/20) of Australian units.
Of units with a written policy or standard practice,
these contained: regular recorded nursing observations
of the site in 88% (21/24), keeping the skin over the tip
of the IV catheter visible in 75% (18/24), and a saline
flush before administration of potentially harmful sub-
stances in 58% (14/24).
Table 2 Staging of extravasation injuries [17] as adapted
from Millan [10]
Stage Characteristics
I Painful intravenous site, no erythema, no swelling
II Painful intravenous site, slight swelling, no blanching, good
pulse below intravenous site, brisk capillary refill below
intravenous site
III Painful intravenous site, marked swelling, blanching, skin cool to
touch, good pulse below intravenous site, brisk capillary refill
below intravenous site
IV Painful intravenous site, very marked swelling, blanching, skin
cool to touch, decreased or absent pulse, capillary refill over 4 s,
skin breakdown or necrosis.
Restieaux et al. BMC Pediatrics 2013, 13:34 Page 3 of 5
http://www.biomedcentral.com/1471-2431/13/3485% (22/26) of units permit the infusion of TPN via
peripheral access. In addition, 58% (15/26) of units
have concentrated TPN solutions available for exclu-
sive central use (e.g. containing 12.5–15% dextrose).
However nine of the units that do infuse TPN periph-
erally qualified their answer with specific comments
such as: “used reluctantly when no other options
available”, “prefer and encourage use of central / long
line, but allow peripheral”, “only when swift transition
to milk anticipated”, and “occasionally, for short term
use when central IV access not available”.
69% (18/26) of the units allow dopamine/inotropes to
be infused via a peripheral line. However ten of these
units made additional clarifying comments such as
“short term only whilst central access being obtained”,
and “if we have no other choice”. 50% (13/26) of units
keep a list of drugs which are particularly likely to cause
significant EI.
Treatment
Regarding the treatment of EI, 65% (17/26) of units have
a written policy, with another 27% (7/26) having a stand-
ard practice. The remaining 8% (2/26) have neither.
Comparing the countries, 83% (5/6) of the New Zealand
units have a written policy, compared to 60% (12/26) of
Australian units.
To assess severity of EI, 58% (14/24) of units with a
written policy or standard practice, use a staging system.
One unit, without a formal staging system, uses clinical
photographs to monitor severity.
In those with a written policy/standard practice, man-
agement included: immediate line removal 88% (21/24)
(the remaining units remove the line following specific
treatments); elevation of the limb 63% (15/24); a saline
washout via small incisions/punctures around the ex-
travasation site 67% (16/24); the use of hyaluronidase
38% (9/24); and a warm or cold compress in 4% (1/24).
No units reported current use of a liposuction technique.
If EI occurred with a vasoactive substance (e.g. dopa-
mine or other inotrope), other than the above tech-
niques, 27% (7/26) of units used a specific antidote e.g.
Phentolamine or nitroglycerine.
Complications
Frequency of referral to plastic surgical services was
considered. 38% (10/26) of units referred the majority of
patients, while 8% (2/26) never requested a plastic
surgery referral. Specific comments regarding criteria
for review included: “grade 3 or 4 injury”; “early if
skin loss looks likely”; and “large area of extravasation,
discolouration, and ulceration”.
Finally, we explored unit experience with severe and/or
life threatening complications of central or peripheral EI.
92% (24/26) had experienced a significant extravasationcomplication. Central injuries reported included: cardiac
(tamponade) in 50% (13/26), with associated deaths in
2 units; hepatic injury in 38% (10/26); peritoneal in 31%
(8/26); retroperitoneal in 12% (3/26); and pleural in
27% (7/26). Peripheral injuries reported included: limb
endangering in 23% (6/26).
Discussion
Extravasation injury as a complication of neonatal inten-
sive care remains an important cause of iatrogenic mor-
bidity and mortality. 92% of units surveyed reported
having experienced a significant extravasation incident.
While much of the focus and concern regarding EI cen-
tres around peripheral venous access, the occurrence of
life-threatening central complications is high, with half
the units in this survey reporting experience of cardiac
tamponade, with some associated deaths. This highlights
the importance of vigilance and monitoring in both cen-
tral and peripheral IV access.
As the complexity of neonatal care increases, NICUs
are increasingly using evidence-based practice protocols.
This is particularly important in an environment where
monitoring and management is provided by front-line
nursing and medical staff at varying levels of training.
Our survey reveals that approximately two thirds of
Australian and New Zealand NICUs have protocols for
the prevention and management of EI; however, as pre-
viously noted in the UK, considerable diversity exists be-
tween units regarding practice.
It is clear that a number of techniques are being
employed for prevention and monitoring of EI. Regard-
ing peripheral IV lines: More than three-quarters of
units surveyed reported a policy of regular nursing ob-
servations and ensuring IV site visibility, as originally
described by Millan [10]. Over half the units have con-
centrated TPN preparations for exclusive use in central
lines, with 15% disallowing peripheral TPN altogether.
Based on many qualifying comments received to this
question, it is clear most units take a cautious approach
to peripheral TPN. The practice of peripheral dopamine
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significant qualifications and caution, and some
disallowing it altogether. Education and identification of
preparations posing risk is clearly an important pre-
ventative strategy. 50% of units currently identify and
document preparations posing particular risk. Regarding
central lines, it is well recognised these carry a risk of
potentially serious harm [11]. Nevertheless, it is possible
to have a low rate of serious and life-threatening com-
plications with strict adherence to safety criteria [12].
In terms of treatment, while most agree on line re-
moval, subsequent steps vary. Much of this diversity
may be explained by the paucity of robust evidence
in the literature. 38% currently use hyaluronidase.
Hyaluronidase is an enzyme which breaks down constit-
uents of the extracellular matrix, leading to increased
diffusion and a subsequent decrease in concentration of
the toxic infusate substance [13]. The benefits of this in
EI have been shown in animal studies and in a number
of case reports in neonates [6,7,13-16]. However, as
hyaluronidase is generally used in conjunction with the
multiple puncture and saline wash-out technique, it is
unclear whether it adds anything over saline alone [17].
Techniques such as multiple skin puncture and saline
flush with or without hyaluronidase are invasive, and
carry some morbidity. Accurate case selection is vital.
Using a staging system (Table 1) is used by over half of
the units in this survey, and the practice is referenced in
numerous previous papers [1,17,18]. This allows proto-
cols to be devised which guide treatment based on injury
severity. For example, stage I and II injuries often do not
require treatment, while stage III and IV are likely to re-
quire intervention [1,17]. Another strategy is greater in-
volvement of plastic surgical services in decision making
around EI. This is now used by over a third of units, for
the majority of their EIs. Whatever the method used,
with increasing data on the benefits of these or similar
treatment techniques, accurate and prompt assessment
and treatment is essential (Table 2).
While TPN would be the most implicated agent in
EI, dopamine and other catecholamines, widely used as
a treatment to support the maintenance of cardiac out-
put and BP, are notorious for causing EI due to their
vasoactive properties [3]. The extravasation of dopa-
mine leads to the activation of alpha-adrenoreceptors in
the peripheral vasculature, [19] resulting in vasocon-
striction and subsequent tissue hypoxia [20]. Various
treatment regimes aim to prevent/interrupt this cas-
cade, e.g. phentolamine [9] and nitroglycerin ointment,
[21,22]. Phentolamine antagonises alpha-adrenergic re-
ceptors, preventing vasoconstriction and subsequent tis-
sue necrosis, [19] while nitroglycerin acts on vascular
smooth muscle in arteries and veins, leading to vaso-
dilation and increased perfusion of tissues [21]. Despite69% of the units administering vasoactive substances
(e.g. dopamine) by peripheral venous access, only 25%
use a specific antidote, such as phentolamine or nitro-
glycerin ointment, in the treatment of catecholamine-
induced EI.
This is the first survey investigating prevention and
management of extravasation injury in Australian and
New Zealand neonatal intensive care units. Responses
were obtained from senior clinicians with close to 100%
response rate, ensuring that this survey provides an ac-
curate and reliable picture of the current practice.
Conclusions
Australian and New Zealand tertiary neonatal units
clearly recognise EI as an important cause of iatrogenic
morbidity and mortality. Significant variation still exists
among units with regards to guidelines for both preven-
tion and management of EI. Pending further research to
inform best practice in this area, neonatal staff should
remain vigilant, ensuring that guidelines for the preven-
tion and treatment of EI are available, and conscien-
tiously followed.
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